Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies
Sign Up to like & getrecommendations! Published in 2025 at "Xenobiotica"
DOI: 10.1080/00498254.2025.2453983
Abstract: Abstract Dolutegravir (DTG) is a key drug used to treat human immunodeficiency virus type-1 (HIV-1) infections. Adverse events (AEs) of DTG treatment, including headache, anxiety, depression, insomnia, and abnormal dreams, are influenced by sex, body… read more here.
Keywords: glucuronidation; glucuronidation activity; diphosphate glucuronosyltransferase; dtg glucuronidation ... See more keywords